Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16774171 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL30255407 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL18352432 | 0.93 | ADORA3 (0.86) | ADORA3KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL30255447 | 0.88 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL16774178 | 0.88 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL20122173 | 0.88 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL21758636 | 0.87 | ADORA3 (1.00) | ADORA3KCNH2 | |
| SCHEMBL20122111 | 0.87 | ADORA3 (1.00) | ADORA3KCNH2 | |
| SCHEMBL16774182 | 0.87 | ADORA3 (1.00) | ADORA3KCNH2 | |
| SCHEMBL10323827 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | UNIVERSITY OF MARYLAND, BALTIMORE | 2022-04-21 | — | — | US | disclosed |
| US-10577368-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-03 | — | — | US | disclosed |
| US-9963450-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577368-B2 | A3 adenosine receptor agonists | ADORA3, ADORA2B, ADORA1 | ADORA3 1/4885KCNH2 463/4885SLC6A2 723/4885 |
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885KCNH2 436/4885SLC6A2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.